T-Therapeutics: Valuation, Funding & Investors
T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge. The company was created to harness the power of T cell biology, to create safe and effective treatments for cancer and autoimmune disease. T-Therapeutics is developing a pipeline of first-in-class drugs that are intended to become transformative medicines, reshaping the clinical landscape for patients with cancer or autoimmune diseases.
Leadership & Board
- Current Number of Employees
- 66
- Current LinkedIn Followers
- 8,536
Latest Estimated Valuation
- Total Amount Raised
- $91M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $91M
- Latest Funding Round
- Series A
Company Momentum
PositiveT-Therapeutics LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
T-Therapeutics had 66 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
T-Therapeutics had 8,536 followers as of November 16, 2026. The number of followers increased by 224 (2.69%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Nov 13, 2025 | Series A | $91.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Tencent | Series A |
| BGF | Series A |
| Digitalis Ventures | Series A |
| F-Prime | Series A |
| Sofinnova Partners | Series A |
| Sanofi Ventures | Series A |
| Cambridge Innovation Capital | Series A |
| University of Cambridge Venture Fund | Series A |
Similar Companies
A snapshot of private companies similar to T-Therapeutics, helping you discover and navigate related company profiles.
Related News and Analysis








